In today’s shifting landscape, pharma, biotech and medtech SMEs are under increasing pressure to sharpen their messaging and demonstrate value in an increasingly competitive funding environment. The focus on SMEs from big pharma to supplement pipelines, has only heightened the need for smaller innovators to differentiate themselves.

This focused roundtable will explore strategies for pharma, biotech and medtech SMEs looking to attract investment to scale from preclinical into the clinic and the development of a compelling investment proposal to facilitate this. The following topics will be covered:

Agenda

08:00 Arrival with tea/coffee and breakfast

08:20 Introduction to the session followed by roundtable discussion on the following elements:

•    IP is the main asset – discussion on strategies to optimise IP position
•    Common pitfalls to avoid - making the IP a business asset and not just a financial burden
•    Building the right team to provide confidence in delivery
•    Developing the clinical development plan and route to market
•    Defining the value proposition and key (experimental) inflection points.

Speakers

Christopher Floyd
MA, MBBS, DPM, PhD, MRCP, FHEA, FFPM, FBPhS
Executive Medical Director, Early Development      
transScrip   
Chris is an expert in translational medicine and clinical pharmacology, with dual accreditation in General Internal Medicine and Clinical Pharmacology & Therapeutics. He leads early development and first-in-human studies, helping clients accelerate the transition from preclinical research to the clinic, often as interim Chief Medical Officer.

Gareth Probert
UK and European Patent Attorney
EIP
Gareth is head of the EIP Elements practice group working in the pharmaceutical and chemical sectors. His practice focusses on pharma, biopharma and medtech innovations, and also contentious proceedings. His team handle high value and complex patent matters, often in collaboration with his litigation colleagues at EIP.

Tim Belcher
UK and European Patent Attorney
EIP
Tim is a partner in the EIP Elements practice group and his practice focusses on pharma, biopharma and medtech innovations.  Tim leads EIP’s Stratiphy offering, which provides tailored IP strategic advice to (bio)pharma SMEs, with a focus on leveraging IP to attract investment and maximise business value.

09:25 Wrap-up

09:00 Close

Attendance: This event is designed for pharma, biotech and medtech companies. Attendance at this event is free of charge and by invitation only. To express your interest in attending, please contact [email protected] at your earliest convenience.